Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
The same trial that sent Summit up 272% sees the stock crash 36%.
